Lake Street Downgrades Assertio to Hold, Price Target Cut to $18
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy ASRT?
As previously reported, Lake Street downgraded Assertio to Hold from Buy with a price target of $18, down from $45, after the company announced it will be acquired by Garda Therapeutics for $18 per share, or $125.1M in total, plus a non-tradeable CVR tied to Sprix milestones. Assertio retains a 20-day go-shop period to entertain competing bids, though given that more than 35 third parties were already engaged during the strategic review, the firm sees limited probability of a superior offer, the analyst added.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.040
Low
35.00
Averages
40.00
High
45.00
Current: 18.040
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Garda to Initiate Tender Offer for Assertio Update
- Tender Offer Timeline: Garda Therapeutics plans to commence its tender offer for all outstanding shares of Assertio on April 29, 2026, marking a critical milestone in the acquisition process that is expected to have a direct impact on shareholder value.
- Acquisition Price Set: As announced on April 8, 2026, Garda will acquire Assertio at $18.00 per share in cash, totaling $125.1 million, reflecting a strong recognition of Assertio's value in the market.
- Window-Shop Provision: The 20-day 'window-shop' period allows Assertio to engage with other potential buyers, and if a superior bid arises, the Board can terminate the agreement with a reduced breakup fee, enhancing shareholder options and potential value.
- Market Reaction Anticipation: The announcement of this tender offer is likely to attract market attention towards Assertio's stock, prompting investors to closely monitor subsequent SEC filings for critical information regarding the terms and conditions of the transaction.
See More
GARDA TO LAUNCH TENDER OFFER FOR ASSERTIO HOLDINGS INC SHARES ON APRIL 29, 2026
- Tender Offer Announcement: Aserto Holdings has announced a tender offer for its shares, set to commence on April 29, 2026.
- Shareholder Engagement: The tender offer aims to engage shareholders and provide them with an opportunity to sell their shares back to the company.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Whitestone REIT (NYSE: WSR) for its sale to Ares Management Corporation at $19.00 per share, potentially violating fiduciary duties to shareholders.
- Merger Implications: The merger between McCormick & Company (NYSE: MKC) and Unilever's Foods business will result in McCormick shareholders owning 35.0% of the combined entity, which may affect shareholder rights.
- Acquisition Scrutiny: Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) is under investigation regarding its merger with American Ocean Minerals Corporation, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations aimed at advocating for investors affected by securities fraud and corporate misconduct, highlighting its successful track record in recovering losses for defrauded investors.
See More
Monteverde Law Firm Investigates Multiple REIT Transactions
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Whitestone REIT and Ares Management, with Whitestone shareholders expected to receive $19.00 per share in cash, significantly enhancing shareholder returns on their investments.
- Assertio Transaction Details: In the deal between Assertio Holdings and Garda Therapeutics, shareholders are expected to receive $18.00 in cash per share plus a contingent value right based on specific milestones, a structure that may attract more investor interest in the company's future growth potential.
- Enhabit Shareholder Vote: Enhabit Inc.'s transaction with Kinderhook Industries is expected to provide shareholders with $13.80 per share in cash, with the shareholder vote scheduled for May 12, 2026, a critical date that will influence the final outcome of the transaction.
- Select Medical Transaction Overview: Shareholders of Select Medical Holdings Corporation are expected to receive $16.50 per share in cash, with the transaction led by Select Medical executives and directors, a structure that may enhance governance transparency and increase shareholder trust.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Enhabit, Inc. (NYSE: EHAB) regarding its sale to Kinderhook Industries, LLC for $13.80 per share in cash, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- Shareholder Rights Protection: The law firm encourages Enhabit shareholders to reach out to discuss their rights and options, emphasizing the provision of legal consultations at no cost, ensuring shareholders are not overlooked in the transaction.
- Other Company Investigations: The inquiry also covers Whitestone REIT (NYSE: WSR) with Ares Management Corporation at $19.00 per unit, and Select Medical Holdings Corporation (NYSE: SEM) with its management for $16.50 per share, highlighting a focus on shareholder interests.
- Legal Remedies: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief measures to protect investors' rights, reflecting a commitment to securities law and fiduciary responsibilities.
See More
Halper Sadeh Investigates Assertio Sale to Garda Therapeutics
- Transaction Investigation: Halper Sadeh LLC is investigating the sale of Assertio Holdings, Inc. to Garda Therapeutics for $18.00 per share in cash and a contingent value right, focusing on whether the best possible price was obtained for shareholders.
- Shareholder Rights: The law firm encourages Assertio shareholders to reach out to learn about their rights and options, emphasizing free consultations to ensure shareholders are not overlooked in the transaction process.
- Compliance Issues: The investigation also examines whether Assertio's board violated federal securities laws and fiduciary duties by failing to conduct a fair sales process and disclose all material information, potentially impacting shareholder decisions.
- Potential Remedies: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders to ensure their legal rights are protected.
See More
Garda to Initiate Tender Offer for Assertio Update
- Tender Offer Timeline: Garda Therapeutics plans to commence its tender offer for all outstanding shares of Assertio on April 29, 2026, marking a critical milestone in the acquisition process that is expected to have a direct impact on shareholder value.
- Acquisition Price Set: As announced on April 8, 2026, Garda will acquire Assertio at $18.00 per share in cash, totaling $125.1 million, reflecting a strong recognition of Assertio's value in the market.
- Window-Shop Provision: The 20-day 'window-shop' period allows Assertio to engage with other potential buyers, and if a superior bid arises, the Board can terminate the agreement with a reduced breakup fee, enhancing shareholder options and potential value.
- Market Reaction Anticipation: The announcement of this tender offer is likely to attract market attention towards Assertio's stock, prompting investors to closely monitor subsequent SEC filings for critical information regarding the terms and conditions of the transaction.
See More
GARDA TO LAUNCH TENDER OFFER FOR ASSERTIO HOLDINGS INC SHARES ON APRIL 29, 2026
- Tender Offer Announcement: Aserto Holdings has announced a tender offer for its shares, set to commence on April 29, 2026.
- Shareholder Engagement: The tender offer aims to engage shareholders and provide them with an opportunity to sell their shares back to the company.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Whitestone REIT (NYSE: WSR) for its sale to Ares Management Corporation at $19.00 per share, potentially violating fiduciary duties to shareholders.
- Merger Implications: The merger between McCormick & Company (NYSE: MKC) and Unilever's Foods business will result in McCormick shareholders owning 35.0% of the combined entity, which may affect shareholder rights.
- Acquisition Scrutiny: Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) is under investigation regarding its merger with American Ocean Minerals Corporation, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations aimed at advocating for investors affected by securities fraud and corporate misconduct, highlighting its successful track record in recovering losses for defrauded investors.
See More
Monteverde Law Firm Investigates Multiple REIT Transactions
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Whitestone REIT and Ares Management, with Whitestone shareholders expected to receive $19.00 per share in cash, significantly enhancing shareholder returns on their investments.
- Assertio Transaction Details: In the deal between Assertio Holdings and Garda Therapeutics, shareholders are expected to receive $18.00 in cash per share plus a contingent value right based on specific milestones, a structure that may attract more investor interest in the company's future growth potential.
- Enhabit Shareholder Vote: Enhabit Inc.'s transaction with Kinderhook Industries is expected to provide shareholders with $13.80 per share in cash, with the shareholder vote scheduled for May 12, 2026, a critical date that will influence the final outcome of the transaction.
- Select Medical Transaction Overview: Shareholders of Select Medical Holdings Corporation are expected to receive $16.50 per share in cash, with the transaction led by Select Medical executives and directors, a structure that may enhance governance transparency and increase shareholder trust.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Enhabit, Inc. (NYSE: EHAB) regarding its sale to Kinderhook Industries, LLC for $13.80 per share in cash, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- Shareholder Rights Protection: The law firm encourages Enhabit shareholders to reach out to discuss their rights and options, emphasizing the provision of legal consultations at no cost, ensuring shareholders are not overlooked in the transaction.
- Other Company Investigations: The inquiry also covers Whitestone REIT (NYSE: WSR) with Ares Management Corporation at $19.00 per unit, and Select Medical Holdings Corporation (NYSE: SEM) with its management for $16.50 per share, highlighting a focus on shareholder interests.
- Legal Remedies: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief measures to protect investors' rights, reflecting a commitment to securities law and fiduciary responsibilities.
See More
Halper Sadeh Investigates Assertio Sale to Garda Therapeutics
- Transaction Investigation: Halper Sadeh LLC is investigating the sale of Assertio Holdings, Inc. to Garda Therapeutics for $18.00 per share in cash and a contingent value right, focusing on whether the best possible price was obtained for shareholders.
- Shareholder Rights: The law firm encourages Assertio shareholders to reach out to learn about their rights and options, emphasizing free consultations to ensure shareholders are not overlooked in the transaction process.
- Compliance Issues: The investigation also examines whether Assertio's board violated federal securities laws and fiduciary duties by failing to conduct a fair sales process and disclose all material information, potentially impacting shareholder decisions.
- Potential Remedies: Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders to ensure their legal rights are protected.
See More
